BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


SEARCH JOBS

Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address the overtreatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results throughout the cancer patient’s journey, from screening and surveillance, to diagnosis, to treatment selection and monitoring. Genomic Health’s lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of June 30, 2013, more than 19,000 physicians in over 70 countries had ordered more than 375,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.

For more information, please visit, www.GenomicHealth.com
and follow the company on Twitter: @GenomicHealth. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com
, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.


 Key Statistics


Email:
Ownership: Public

Web Site: Genomic Health, Inc.
Employees:
Symbol: GHDX
 



Industry
Medical Device






 Company News
Genomic Health, Inc. (GHDX) Announces Year-End 2013 Financial Results, Provides 2014 Financial Outlook 2/5/2014 6:24:11 AM    More...
Genomic Health, Inc. (GHDX) Announces Results Of Oncotype DX® Colon Cancer Studies Presented At 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium 1/29/2014 7:27:21 AM    More...
Genomic Health, Inc. (GHDX) To Announce Fourth Quarter And Year-End 2013 Financial Results And Host Conference Call On Tuesday, February 4, 2014 1/28/2014 7:56:27 AM    More...
Genomic Health, Inc. (GHDX) Announces Presentation Of New Oncotype DX® Studies Underscoring Unique Value Of The Test In Early-Stage Breast Cancer At The 36th Annual CTRC-American Association for Cancer Research San Antonio Breast Cancer Symposium 12/16/2013 6:22:47 AM    More...
Genomic Health, Inc. (GHDX) Announces Presentation Of Oncotype DX® Studies At The 2013 CTRC-AACR San Antonio Breast Cancer Symposium (Sabcs) 12/4/2013 6:36:26 AM    More...
Genomic Health, Inc. (GHDX) and Almac Group Enter Exclusive In-Licensing Agreement To Develop And Commercialize Anthracycline Chemotherapy Benefit Test For High Risk Breast Cancer 11/25/2013 2:43:17 PM    More...
Genomic Health, Inc. (GHDX) Announces Publication Of Oncotype DX® Prostate Cancer Test Analytical Validation Study 11/22/2013 10:36:59 AM    More...
Genomic Health, Inc. (GHDX) Announces Colon Cancer Publication In Journal of Clinical Oncology Supporting Wider Oncotype DX® Utilization 11/13/2013 11:23:16 AM    More...
Genomic Health, Inc. (GHDX) Announces Third Quarter 2013 Financial Results and Business Progress 11/6/2013 7:35:43 AM    More...
Genomic Health, Inc. (GHDX) Announces Colon Cancer Publication Supporting Wider Oncotype DX® Utilization 11/5/2013 9:16:02 AM    More...
12345678910...

//-->